Quince Therapeutics, Inc. (Nasdaq: QNCX) has announced a significant milestone in its financial restructuring efforts by settling approximately $16.4 million of debt owed to the European Investment Bank (EIB). On March 27, 2026, the company made a payment of $5.5 million on behalf of its subsidiary, Quince Therapeutics S.p.A., effectively discharging all obligations under the finance contract and related guarantee agreement established in July 2020. This settlement not only alleviates a substantial financial burden but also positions Quince to explore strategic alternatives aimed at maximizing shareholder value. CEO Dirk Thye emphasized that this successful settlement removes a critical overhang that had previously constrained the company's operational flexibility. The company is now poised to pursue various strategic options, including potential mergers, asset sales, or other transactions that could enhance its market position. The press release detailing this development was issued on March 30, 2026, and is available as Exhibit 99.1 in the current report on Form 8-K. This proactive step is expected to positively influence investor sentiment and may lead to a favorable adjustment in the company's stock performance as it moves forward with its restructuring plans.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.